MidWestOne Financial Group Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,678 shares of the company’s stock after selling 523 shares during the period. Johnson & Johnson comprises approximately 1.2% of MidWestOne Financial Group Inc.’s holdings, making the stock its 7th largest holding. MidWestOne Financial Group Inc.’s holdings in Johnson & Johnson were worth $2,908,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Sector Gamma AS grew its position in shares of Johnson & Johnson by 0.3% during the 1st quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock worth $15,412,000 after buying an additional 303 shares in the last quarter. Tradewinds Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 1.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock valued at $997,000 after buying an additional 101 shares in the last quarter. Dempze Nancy E raised its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Dempze Nancy E now owns 20,907 shares of the company’s stock worth $2,939,000 after acquiring an additional 80 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Johnson & Johnson by 10.3% during the 2nd quarter. Bessemer Group Inc. now owns 268,577 shares of the company’s stock worth $37,769,000 after acquiring an additional 25,097 shares in the last quarter. Finally, Private Asset Management Inc. raised its stake in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock worth $13,213,000 after acquiring an additional 425 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.
JNJ has been the subject of several recent analyst reports. Raymond James boosted their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target on the stock. in a research note on Tuesday, July 7th. Citigroup upped their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $163.00.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.58 earnings per share. Equities analysts predict that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.73%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s payout ratio is 46.54%.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Dividend Reinvestment Plan (DRIP)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.